Total Payments
$534,649
2024 Payments
$106,737
Companies
21
Transactions
535
Medicare Patients
71
Medicare Billing
$10,200
Payment Breakdown by Category
Other$297,343 (55.6%)
Consulting$180,078 (33.7%)
Travel$43,259 (8.1%)
Food & Beverage$13,239 (2.5%)
Research$718.30 (0.1%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $293,454 | 100 | 54.9% |
| Consulting Fee | $180,078 | 54 | 33.7% |
| Travel and Lodging | $43,259 | 180 | 8.1% |
| Food and Beverage | $13,239 | 193 | 2.5% |
| Honoraria | $3,889 | 6 | 0.7% |
| Unspecified | $718.30 | 1 | 0.1% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$533,931
534 transactions
Research
$718.30
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | $146,597 | 167 | $0 (2024) |
| Seagen Inc. | $118,001 | 110 | $0 (2023) |
| Stemline Therapeutics Inc. | $105,821 | 71 | $0 (2024) |
| Genentech USA, Inc. | $39,425 | 38 | $0 (2022) |
| Gilead Sciences, Inc. | $31,190 | 37 | $0 (2024) |
| PFIZER INC. | $25,961 | 20 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $24,990 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $14,569 | 24 | $0 (2024) |
| Seattle Genetics, Inc. | $10,136 | 14 | $0 (2019) |
| Daiichi Sankyo Inc. | $7,405 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $106,737 | 99 | Stemline Therapeutics Inc. ($55,069) |
| 2023 | $134,901 | 100 | Stemline Therapeutics Inc. ($50,653) |
| 2022 | $81,889 | 91 | PUMA BIOTECHNOLOGY, INC. ($41,351) |
| 2021 | $122,404 | 135 | Seagen Inc. ($53,999) |
| 2020 | $31,656 | 30 | Puma Biotechnology, Inc. ($15,861) |
| 2019 | $26,424 | 37 | Puma Biotechnology, Inc. ($10,507) |
| 2018 | $20,567 | 26 | Daiichi Sankyo Inc. ($7,331) |
| 2017 | $10,070 | 17 | Genentech USA, Inc. ($4,094) |
All Payment Transactions
535 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $122.91 | General |
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $113.52 | General |
| Category: ONC | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: ONC | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $108.95 | General |
| 12/11/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $37.15 | General |
| 12/11/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.90 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: ONC | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: ONC | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $45.89 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $42.75 | General |
| Category: ONC | ||||||
| 12/09/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Oncology | ||||||
| 11/15/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Oncology | ||||||
| 11/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.14 | General |
| 11/04/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| 10/31/2024 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Travel and Lodging | Cash or cash equivalent | $126.77 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | Cash or cash equivalent | $25.69 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $66.24 | General |
| Category: ONC | ||||||
| 10/19/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $54.90 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $718.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 27 | 62 | $23,698 | $3,631 |
| 2020 | 3 | 44 | 78 | $22,614 | $6,570 |
Total Patients
71
Total Services
140
Medicare Billing
$10,200
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 13 | 48 | $18,336 | $2,785 | 15.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 14 | 14 | $5,362 | $845.74 | 15.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 38 | $10,374 | $3,464 | 33.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 19 | $7,177 | $1,777 | 24.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 17 | 21 | $5,063 | $1,329 | 26.3% |
About Vijayakrishna Gadi, M.D. PHD
Vijayakrishna Gadi, M.D. PHD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053358671.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Vijayakrishna Gadi, M.D. PHD has received a total of $534,649 in payments from pharmaceutical and medical device companies, with $106,737 received in 2024. These payments were reported across 535 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($293,454).
As a Medicare-enrolled provider, Gadi has provided services to 71 Medicare beneficiaries, totaling 140 services with total Medicare billing of $10,200. Data is available for 2 years (2020–2022), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Seattle, WA
- Active Since 06/01/2006
- Last Updated 03/05/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053358671
Products in Payments
- NERLYNX (Drug) $129,734
- TUKYSA (Drug) $121,208
- Orserdu (Drug) $86,585
- Phesgo (Biological) $33,005
- Trodelvy (Drug) $31,069
- IBRANCE (Drug) $16,708
- Nerlynx (Drug) $10,507
- KISQALI (Drug) $8,224
- Herceptin (Biological) $7,997
- ENHERTU (Biological) $7,902
- ELZONRIS (Drug) $7,800
- ADCETRIS (Biological) $6,860
- PIQRAY (Drug) $6,027
- LIV1A (Biological) $3,119
- TECENTRIQ (Biological) $2,100
- BTX (Device) $774.07
- APTIMA (Device) $680.69
- BYL719 (Drug) $669.00
- Perjeta (Biological) $282.00
- KEYTRUDA (Biological) $150.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
John Pagel, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732
Dr. Rebecca Kruse-Jarres, M.d, M.D
Hematology & Oncology — Payments: $288,284
Hematology & Oncology $288,284